BRIEF published on 02/28/2025 at 07:35, 1 year 6 months ago ABIONYX strengthens its commitment against LCAT Deficiency Rare Disease Marketing Authorization LCAT Deficiency Biomedicine Norum Disease
PRESS RELEASE published on 02/28/2025 at 07:30, 1 year 6 months ago Inside Information / Other news releases ABIONYX renews commitment to treat LCAT Deficiency (Norum's disease) and provides updates on advances, including submission of Marketing Authorization Application and Orphan Disease Designation ABIONYX LCAT Deficiency Rare Disease Day Marketing Authorization Application Orphan Disease Designation
BRIEF published on 02/27/2025 at 19:25, 1 year 6 months ago ABIONYX Pharma Reports Stable Revenue and Cash Position for 2024 2024 Financial Results Innovative Therapies ABIONYX Pharma Compassionate Access CRO Industry
PRESS RELEASE published on 02/27/2025 at 19:20, 1 year 6 months ago Inside Information / Information on annual revenues ABIONYX Pharma reports €4.6m revenue and €3.2m cash at the end of Q4 2024. Details on business activities and financial performance included Revenue Cash Position Financial Update Biopharma ABIONYX Pharma
BRIEF published on 02/20/2025 at 07:35, 1 year 6 months ago ABIONYX Pharma receives €8.7 million in support for its sepsis project Financial Support France 2030 ABIONYX Pharma Sepsis Biomedicine
BRIEF published on 12/11/2024 at 12:16, 1 year 9 months ago Threshold crossing by the CDC in ABIONYX PHARMA Voting Rights CDC Threshold Crossing ABIONYX Pharma Bpifrance Participations
BRIEF published on 12/11/2024 at 12:13, 1 year 9 months ago Threshold crossing by Bpifrance in ABIONYX PHARMA Voting Rights Actions Threshold Crossing Bpifrance ABIONYX
BRIEF published on 12/10/2024 at 10:51, 1 year 9 months ago Threshold crossing by Cyrille Tupin at ABIONYX PHARMA Voting Rights Actions Threshold Crossing ABIONYX Pharma Cyrille Tupin
BRIEF published on 11/14/2024 at 19:05, 1 year 10 months ago ABIONYX Pharma: Third quarter 2024 financial report Biotechnology Treasury Turnover Q3 2024 ABIONYX Pharma
PRESS RELEASE published on 11/14/2024 at 19:00, 1 year 10 months ago Quarterly financial reporting / Third quarter financial report ABIONYX Pharma reports Q3 2024 revenue of €3.4m and cash position of €4.1m before IRIS Pharma's CIR receipt. General Meeting on November 28, 2024, at 2.00 pm CET Cash Position General Meeting Biotech Company ABIONYX Pharma Revenue Update
Published on 09/17/2026 at 13:00, 10 minutes ago Organto Foods Strengthens Scalable European Operating Platform and Launches AI Powered Operational Transformation
Published on 09/17/2026 at 13:00, 10 minutes ago Gold Terra Announces Fall Drilling with Three (3) Rigs Active on the Con Mine, Yellowknife, NWT
Published on 09/17/2026 at 13:00, 10 minutes ago NiobiumX Mining Inc. Appoints Athabasca Basin Discovery Geologist Erik Sehn to Board of Directors
Published on 09/17/2026 at 12:00, 1 hour 10 minutes ago Banyan Gold Intersects 1.05 g/t Gold over 52.8 metres and Bonanza-Grade Gold at Powerline Deposit, AurMac, Yukon, Canada
Published on 09/17/2026 at 10:00, 3 hours 10 minutes ago Eagle Plains Reports Additional Results from Drilling at the Don Lake Uranium Project, Saskatchewan
Published on 09/17/2026 at 13:05, 5 minutes ago Aurzen Expands Its Presence in Germany with Launch on Joybuy, Bringing EAZZE D1 and ZIP to More Consumers
Published on 09/17/2026 at 13:00, 10 minutes ago Original-Research: Smartbroker Holding AG (von GBC AG): BUY
Published on 09/17/2026 at 13:00, 10 minutes ago Medartis Group acquires M.A.R.C. Institute to establish its first surgical education center in the US
Published on 09/17/2026 at 13:00, 10 minutes ago Ascory Bank AG enters into a strategic, long-term partnership with Mount Street to deliver outsourced credit administration and surveillance
Published on 09/16/2026 at 17:45, 19 hours 25 minutes ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 6 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 19 hours ago Report on the Combined General Meeting of the 10th of September 2026
